155 related articles for article (PubMed ID: 36929648)
1. Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS).
Yerton M; Winter A; Gelevski D; Addy G; Kostov A; Lieberman C; Weber H; Doyle M; Kane G; Cohen C; Parikh N; Burke KM; Rohrer M; Stirrat T; Bruno M; Hochman A; Luppino S; Scalia J; D'Agostino D; Sinani E; Yu H; Drake K; Hagar J; Sherman AV; Babu S; Berry JD; Cudkowicz ME; Paganoni S
Muscle Nerve; 2023 Jun; 67(6):456-463. PubMed ID: 36929648
[TBL] [Abstract][Full Text] [Related]
2. Multicenter expanded access program for access to investigational products for amyotrophic lateral sclerosis.
Neel DV; Baselga-Garriga C; Benson M; Keegan M; Chase M; D'Agostino D; Drake K; Hagar JL; Hasenoehrl MG; Kulesa-Kelley J; Leite A; Mohapatra S; Portaro SM; Pothier LM; Rosenthal J; Sherman AV; Yu H; McCaffrey A; Ho D; Luppino S; Bedlack R; Heitzman D; Ajroud-Driss S; Katz J; Felice K; Whitaker C; Ladha S; Alameda G; Locatelli E; Qureshi IA; Hotchkin MT; Hayden MR; Cudkowicz ME; Babu S; Berry JD; Paganoni S
Muscle Nerve; 2024 Aug; 70(2):232-239. PubMed ID: 38842106
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of anti-CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol.
Gelevski D; Addy G; Rohrer M; Cohen C; Roderick A; Winter A; Carey J; Scalia J; Yerton M; Weber H; Doyle M; Parikh N; Kane G; Ellrodt A; Burke K; D'Agostino D; Sinani E; Yu H; Sherman A; Agosti J; Redlich G; Charmley P; Crowe D; Appleby M; Ziegelaar B; Hanus K; Li Z; Babu S; Nicholson K; Luppino S; Berry J; Baecher-Allan C; Paganoni S; Cudkowicz M
Muscle Nerve; 2023 May; 67(5):354-362. PubMed ID: 36533976
[TBL] [Abstract][Full Text] [Related]
4. Expanded Access Programme: looking for a common definition.
Iudicello A; Alberghini L; Benini G; Mosconi P
Trials; 2016 Jan; 17():21. PubMed ID: 26758369
[TBL] [Abstract][Full Text] [Related]
5. The current state of understanding of oncology expanded access programs in Malaysia.
Yong FL; Tan WC
Med J Malaysia; 2024 Mar; 79(2):191-195. PubMed ID: 38553925
[TBL] [Abstract][Full Text] [Related]
6. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
[TBL] [Abstract][Full Text] [Related]
7. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
Puthumana J; Miller JE; Kim J; Ross JS
JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
[TBL] [Abstract][Full Text] [Related]
8. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
[TBL] [Abstract][Full Text] [Related]
9. An expanded access protocol of RT001 in amyotrophic lateral sclerosis-Initial experience with a lipid peroxidation inhibitor.
Yerton M; Winter A; Kostov A; Lieberman C; Gelevski D; Weber H; Doyle M; Kane G; Parikh N; Burke KM; Rohrer M; Stirrat T; Bruno M; Hochman A; Luppino S; Scalia J; Skoniecki D; D'Agostino D; Sinani E; Yu H; Sherman AV; Babu S; Berry JD; Midei MG; Milner PG; Cudkowicz ME; Paganoni S
Muscle Nerve; 2022 Oct; 66(4):421-425. PubMed ID: 35765222
[TBL] [Abstract][Full Text] [Related]
10. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study.
Kiefer P; Kirschner J; Pechmann A; Langer T
Orphanet J Rare Dis; 2020 Jul; 15(1):194. PubMed ID: 32727502
[TBL] [Abstract][Full Text] [Related]
13. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
[TBL] [Abstract][Full Text] [Related]
14. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.
Radunovic A; Annane D; Rafiq MK; Brassington R; Mustfa N
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD004427. PubMed ID: 28982219
[TBL] [Abstract][Full Text] [Related]
15. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
[TBL] [Abstract][Full Text] [Related]
16. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
[TBL] [Abstract][Full Text] [Related]
17. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
19. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2012 Dec; 12():CD005225. PubMed ID: 23235621
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
